Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is a U.S.-based, clinical-stage healthcare company headquartered in the Rockville/Gaithersburg, Maryland area and founded in 2012. The company’s core business approach centers on developing oncology therapeutics designed to enhance the effects of radiation therapy. According to the company’s description, its current portfolio includes Ropidoxuridine ...Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is a U.S.-based, clinical-stage healthcare company headquartered in the Rockville/Gaithersburg, Maryland area and founded in 2012. The company’s core business approach centers on developing oncology therapeutics designed to enhance the effects of radiation therapy. According to the company’s description, its current portfolio includes Ropidoxuridine (an orally administered halogenated pyrimidine intended for patients with brain tumors and soft tissue sarcomas) and Doranidazole (an injectable candidate formulated to make oxygen-deprived tumor cells more responsive to radiation, targeting cancers of the pancreas, lungs, and liver).
In parallel with its clinical pipeline, Shuttle Pharmaceuticals also positions itself as a software/technology-enabled drug discovery company. The company states that it owns and uses a pharmaceutical software artificial intelligence (AI)–driven platform for molecular discovery and early-stage drug development. This combination can support the company’s operational model by helping identify and prioritize molecular candidates earlier in the development process, potentially improving the efficiency of translational research activities that typically precede clinical trials.
From a cost and execution perspective, companies like SHPH generally rely heavily on research and development spending, including preclinical work, formulation, regulatory activities, and clinical trial operations. While the provided dataset includes numerous financial ratios, it does not provide enough detail to reliably describe specific product costs, bill-of-materials (BOM) structures, or segment-level profitability. Therefore, the key takeaway is that Shuttle’s value creation is primarily driven by progress in clinical-stage development and the ability to convert R&D and platform efforts into viable therapeutic programs.
Key people include Christopher Robert Cooper, who is described as President, CEO, and Founder (and is also noted in leadership context as an Interim Co-CEO in certain announcements). The company’s leadership also includes scientific/clinical oversight through board and executive roles (e.g., the chairman and co-CEO referenced as overseeing scientific and clinical trial activity).
Overall, Shuttle Pharmaceuticals’ strategy is to advance targeted, radiation-sensitizing oncology agents through clinical development while leveraging its AI-driven discovery platform to support early-stage candidate identification and development, with the goal of improving outcomes for cancer patients.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-11.7M
-28.2%
+17.7%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-9.5M
-29.4%
-148.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
10.3%
-93.8%
-37.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.06x
-95.6%
+369.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
